To harness dendritic cell science and train the immune system with unprecedented specificity. We're committed to delivering breakthrough clinical protocols that achieve 94% immune activation rates and transformative survival outcomes for patients globally.
To be the leading global provider of precision immunotherapy across 42+ locations with Breakthrough Designation status. We envision a future where protocol sets the standard for intelligent immunity training with <0.5% adverse events and 3.2× survival improvements.
Immune activation rate in clinical trials.
Survival improvement demonstrated.
Patients in Phase III protocol.
Severe adverse events rate.